MARTINSRIED/MUNICH, Germany, Sept. 25 /PRNewswire-FirstCall/ --
Waltham, Mass. and Princeton, N.J. -- GPC Biotech AG (Frankfurt Stock
Exchange: GPC; TecDAX 30; Nasdaq: GPCB) today announced that it will hold a
conference call today, Monday, September 25, 2006 to discuss positive
results from the satraplatin pivotal phase 3 trial in second-line hormone
refractory prostate cancer announced yesterday.
The call will be held today at 14:00 CEST/8:00 AM EDT. Participants may
listen via live webcast, accessible through the GPC Biotech Web site at
http://www.gpc-biotech.com or via telephone. A replay will be available via
the Web site following the live event.
The dial-in numbers for the call are as follows:
European participants: 0049-(0)69-5007-1846
U.S. participants: 1-800-573-4752 (toll-free)
GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs.
GPC Biotech's lead product candidate - satraplatin - has achieved
target enrollment in a Phase 3 registrational trial as a second-line
chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA
has granted fast track designation to satraplatin for this indication, and
GPC Biotech has begun the rolling NDA submission process for this compound.
GPC Biotech is also developing a monoclonal antibody with a novel
mechanism-of-action against a variety of lymphoid tumors, currently in
Phase 1 clinical development, and has ongoing drug development and
discovery programs that leverage its expertise in kinase inhibitors. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany), and its wholly
owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton,
New Jersey. For additional information, please visit GPC Biotech's Web site
at http://www.gpc-biotech.com.
For further information, please contact:
GPC Biotech AG
Fraunhoferstr. 20
82152 Martinsried/Munich, Germany
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 781 890 9007 X267 or +1 609 524 1000
usinvestors@gpc-biotech.com
Additional Media Contacts:
In Europe:
Maitland Noonan Russo
Brian HudspithPhone: +44(0)20 7379 5151
bhudspith@maitland.co.uk
In the U.S.:
Noonan Russo
David Schull
Phone: +1 858 546-4810
david.schull@eurorscg.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com/
CONTACT:
Martin Braendle, Director, Investor Relations
& Corporate Communications, +49-89-8565-2693, ir@gpc-biotech.com,
or Laurie Doyle, Director, Investor Relations & Corporate
Communications, +1-781-890-9007 ext. 267, or +1-609-524-1000,
usinvestors@gpc-biotech.com, both of GPC Biotech AG; or In the
U.S.: David Schull of Noonan Russo, +1-858-546-4810,
david.schull@eurorscg.com; or In Europe: Brian Hudspith of
Maitland Noonan Russo, +44-20-7379-5151, bhudspith@maitland.co.uk
|
